Top Page
CervoMed
(NASDAQ:CRVO)
CervoMed (CRVO) vs. SPDR S&P 500 ETF (SPY)
CervoMed Business Overview & Revenue Model
CervoMed Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 322.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 322.57K | 0.00 | 0.00 | 0.00 | 0.00 | -103.17K |
| EBITDA | -26.89M | -18.23M | -7.81M | -5.80M | -15.94M | -15.76M |
| Net Income | -25.58M | -16.29M | -2.17M | -5.80M | -24.10M | -14.19M |
Balance Sheet | ||||||
| Total Assets | 30.61M | 43.08M | 9.97M | 4.16M | 37.84M | 27.73M |
| Cash, Cash Equivalents and Short-Term Investments | 27.29M | 38.92M | 7.79M | 4.09M | 37.31M | 18.52M |
| Total Debt | 0.00 | 0.00 | 0.00 | 12.41M | 0.00 | 149.16K |
| Total Liabilities | 4.60M | 3.88M | 2.60M | 13.16M | 2.93M | 2.92M |
| Stockholders Equity | 26.01M | 39.20M | 7.38M | -9.00M | 34.91M | 24.81M |
Cash Flow | ||||||
| Free Cash Flow | -24.93M | -16.53M | -7.45M | -2.57M | -14.50M | -13.55M |
| Operating Cash Flow | -24.93M | -16.53M | -7.45M | -2.57M | -14.50M | -13.55M |
| Investing Cash Flow | 22.03M | -28.66M | 0.00 | 0.00 | 4.00K | 0.00 |
| Financing Cash Flow | 4.59M | 46.40M | 11.15M | 0.00 | 33.30M | 17.89M |
CervoMed Technical Analysis
CervoMed Risk Analysis
CervoMed Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $121.72M | -1.12 | -103.99% | ― | 250.00% | 15.15% | |
52 Neutral | $316.52M | -0.37 | -156.87% | ― | 2925.73% | -294.29% | |
52 Neutral | $42.54M | -0.26 | -191.12% | ― | ― | -24.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $65.51M | -2.51 | -71.42% | ― | -38.81% | -76.96% | |
44 Neutral | $49.82M | -9.05 | -40.32% | ― | 56.52% | 75.22% |
CervoMed Corporate Events
On January 8, 2026, CervoMed Inc. disclosed that it has made an investor presentation available on its website under the “Investors – Events and Presentations” section, summarizing information about its business, clinical studies, development plans, financial position and related matters. The company noted that its representatives may periodically use this presentation, with possible non-material modifications, in conferences and investor meetings, emphasized that the materials should be considered in the context of its broader SEC filings and public announcements, and clarified that the furnished information is not deemed “filed” for purposes of the Exchange Act and does not carry the associated liability unless specifically incorporated by reference in future regulatory filings.
The most recent analyst rating on (CRVO) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.
CervoMed announced new data from its Phase 2b RewinD-LB trial, presented at the 18th Clinical Trials on Alzheimer’s Disease Conference in December 2025, showing that neflamapimod treatment led to improvements in neuroinflammation and neurodegeneration markers in patients with dementia with Lewy bodies. The trial demonstrated significant reductions in plasma GFAP levels and an increase in the Ab42/40 ratio, suggesting that neflamapimod may act on the underlying disease process. These findings reinforce previous studies and support the initiation of a Phase 3 trial, highlighting the potential impact on treatment options for DLB, a condition with no approved treatments in the US or EU.
The most recent analyst rating on (CRVO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.
On November 4, 2025, CervoMed Inc. announced it received alignment from the U.S. FDA on key aspects of its proposed Phase 3 clinical trial for neflamapimod, aimed at treating dementia with Lewy bodies (DLB). The feedback allows CervoMed to proceed with its trial design, which includes a global, randomized, double-blind study involving approximately 300 patients, with the trial set to begin in the second half of 2026. This development marks a significant milestone for CervoMed, reinforcing its scientific approach and providing a regulatory pathway toward potential approval. The trial is designed to exclude patients with Alzheimer’s disease co-pathology and will focus on cognitive and functional decline, with the aim of establishing neflamapimod as a first-in-class treatment for DLB, a condition currently lacking approved therapies.
The most recent analyst rating on (CRVO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.
On October 27, 2025, CervoMed Inc. appointed David Quigley, a former Senior Partner at McKinsey & Company, to its Board of Directors. Quigley’s extensive experience in life sciences and private equity is expected to support CervoMed’s strategic initiatives as it prepares for key milestones, including FDA feedback on its planned Phase 3 trial for dementia with Lewy bodies. His appointment expands the Board to eight members and is seen as a strategic move to leverage his business strategy and financial insights for advancing CervoMed’s mission and enhancing value for stakeholders.
The most recent analyst rating on (CRVO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.
CervoMed Inc. has made available a presentation on its website, detailing its business, clinical studies, and financial position. This information is intended for use in investor and analyst meetings, and while the company may update this information, it is not obligated to do so unless required by law.
The most recent analyst rating on (CRVO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.